Hospital Clinico Universitario Salamanca
Hospital Clinico Universitario Salamanca
Salamanca, Spain5 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Long-term Extension Study of PCI-32765 (Ibrutinib) | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Blood Protein Disorders, Bronchiolitis Obliterans, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Waldenstrom macroglobulinemia, bronchial disorder, bronchiolitis, bronchiolitis obliterans syndrome, bronchitis, cardiovascular disorder, cryptogenic organizing pneumonia, diffuse large B-cell lymphoma, follicular lymphoma, graft versus host disease, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, leukemia, lung disorder, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, mantle cell lymphoma, monoclonal gammopathy, neoplasm, obstructive lung disease, plasma cell neoplasm, respiratory system disorder, vascular disorder, vascular hemostatic disease | Active, not recruiting | Phase 3 | 2026-10-01 | NCT01804686 | |
| A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 3 | 2026-09-28 | NCT03462719 | |
| NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide | Newly Diagnosed Multiple Myeloma | Recruiting | Phase 3 | 2026-06-25 | NCT05558319 | |
| Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST) | Anitocabtagene Autoleucel; De Novo Multiple Myeloma | Recruiting | Phase 2 | 2025-08-01 | NCT07045909 | |
| Ciltacabtagene Autoleucel in High-Risk Smoldering Multiple Myeloma | High Risk Smoldering Multiple Myeloma | Recruiting | Phase 2 | 2024-10-26 | NCT06574126 |